VRX - Valeant Pharmaceuticals International, Inc.

NYSE - NYSE Delayed Price. Currency in USD
19.71
+0.03 (+0.15%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close19.68
Open19.70
Bid0.00 x 0
Ask0.00 x 0
Day's Range19.20 - 20.39
52 Week Range8.31 - 22.81
Volume23,793,867
Avg. Volume16,185,606
Market Cap6.864B
Beta-0.80
PE Ratio (TTM)5.03
EPS (TTM)3.92
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2010-11-10
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire18 hours ago

    Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes

    LAVAL, Quebec, Dec. 15, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX) (VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly-owned subsidiary of Valeant, to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement date for the Tender Offers on December 18, 2017 (the "Early Settlement Date"). Valeant is the Offeror for the notes issued by it, and VPI is the Offeror for the notes issued by it.

  • CNW Group18 hours ago

    Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes

    Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes

  • TheStreet.comyesterday

    Valeant Pharmaceuticals Stock Still a Dog?

    The drugmaker's stock has rallied about $10 in just a few weeks, so a period of consolidation or sideways movement would be expected.

  • Barrons.comyesterday

    Valeant: A Real Bounceback or a Dead Cat?

    Shares of Valeant Pharmaceuticals International (VRX) are higher on Friday, recovering from a downgrade from JPMorgan yesterday, but investors shouldn't get too comfortable, warns Mizuho Securities.  Analyst Irina Koffler reiterated an Underperform rating on the stock today, although she did raise he price target from $7 to $10. Koffler writes that while 2018 EBITDA guidance may not be "that disappointing," but she's not willing to abandon her bear thesis ahead of it.

  • SmarterAnalystyesterday

    Valeant Pharmaceuticals Intl Inc (VRX) Bear Boosts Price Target Amid Solid Turnaround Efforts

    Valeant Pharmaceuticals Intl Inc (NYSE:VRX) almost shook off a bear from its tail amid some impressive turnaround efforts to "deftly" refinance debt. Mizuho analyst Irina Rivkind Koffler all the same does look for a "negative" reaction to the comeback stock of the Street in terms of the 2018 guide and underscores fears of a dilutive financing event, especially considering the latest rally.

  • ACCESSWIREyesterday

    Today’s Research Reports on Trending Tickers: Catalyst Biosciences and Valeant Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, ...

  • Stocks Skittish on Tax Worries
    InvestorPlaceyesterday

    Stocks Skittish on Tax Worries

    U.S. equities fell on Thursday amid doubts over the fate of the GOP’s tax cut plans. The doubt hit investors after a number of Republican senators expressed reservations about the amount of the child tax credit. In the end, the Dow Jones Industrial Average lost 0.3%, the S&P 500 lost 0.4%, the Nasdaq Composite lost 0.3% and the Russell 2000 lost 1.2%.

  • Why Sanderson Farms, Valeant Pharmaceuticals International, and Criteo Slumped Today
    Motley Fool2 days ago

    Why Sanderson Farms, Valeant Pharmaceuticals International, and Criteo Slumped Today

    Find out the latest company that mentioned the NFL's impact on its business.

  • Barrons.com2 days ago

    Valeant: Down It Goes!

    Everything's been going so well for Valeant Pharmaceuticals International (VRX). See, Valeant has been on quite a run. Since bottoming at $8.51 in April, Valeant's shares have rallied more than 130% as the beleaguered pharmaceutical company sold off assets, and paid down or extended its debt.

  • GuruFocus.com2 days ago

    3 Stocks Move on Thursday

    Nordson, Teva Pharmaceutical rise, Valeant falls

  • SmarterAnalyst2 days ago

    Valeant Pharmaceuticals Intl Inc (VRX) Has A New Bear In Town

    Have Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares just gotten too expensive? Shares are tumbling 10% after a cautious analyst decided it is no longer wise to play it safe, deciding to step away from the sidelines on VRX. The reason? The struggling biotech giant's estimates for the next two years seem too ambitious. Moreover, now after shares have rallied close to 100% from the stock price before the third quarter print, Valeant's valuation simply does not make a "compelling" argument to invest.

  • MarketWatch2 days ago

    These 4 stocks are powering higher

    News and strong technical momentum are behind these gains.

  • Market Realist2 days ago

    Valeant Pharmaceuticals’ Siliq Approved for Plaque Psoriasis

    In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals' (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.

  • TODAY'S CHARTS: Disney to buy 21st Century Fox assets; Teva to cut 25% of workforce; Pier 1 plunges
    Yahoo Finance2 days ago

    TODAY'S CHARTS: Disney to buy 21st Century Fox assets; Teva to cut 25% of workforce; Pier 1 plunges

    Disney (DIS) is spending $52 billion for most of 21st Century Fox’s (FOXA) film and TV assets. Disney shares are up over 2% on the deal news. Disney will also take on about $13 billion in debt.

  • Benzinga2 days ago

    Jim Chanos Compares Bitcoin To Beanie Babies: 'It's A Speculative Mania'

    As far as Jim Chanos is concerned, his hedge fund is different than most. Kynikos investments come not from the budding minds of rookies but from the time-tested partners, themselves. That’s because “the ...

  • MarketWatch2 days ago

    Valeant's stock drops after J.P. Morgan turns bearish

    Shares of Valeant Pharmaceuticals International Inc. dropped 4.3% in premarket trade Thursday, after the drug maker was downgraded at J.P. Morgan, which cited valuation and concerns over patent losses ...

  • Benzinga2 days ago

    Here's What's Coming Up On PreMarket Prep For December 14

    On today's edition of PreMarket Prep, we're discussing the market's reaction to the Twenty-First Century Fox Inc (NYSE: FOXA ) deal with Walt Disney Co (NYSE: DIS ), Pier 1 Imports Inc (NYSE: PIR ) earnings, ...

  • Valeant (VRX) Touches 52-Week High: Is the Stock Officially Back?
    Zacks3 days ago

    Valeant (VRX) Touches 52-Week High: Is the Stock Officially Back?

    Shares of Valeant Pharmaceuticals (VRX) surged more than 2% higher on Wednesday morning, touching a new 52-week high in the process. As we approach the New Year, it is time to ask: is Valeant officially back?

  • TheStreet.com4 days ago

    Cramer: These CEOs Are Creating Value

    Not all stocks are created equal and it's the CEOs who make the difference.

  • Barrons.com4 days ago

    This Porridge Is Too Hot: Valeant Bears Abandon the Stock

    Shares of Valeant Pharmaceuticals International (VRX) are higher Tuesday, and have easily outperformed this year, to the point that shorts may be throwing in the towel. Today, Cantor Fitzgerald's Louise Chen and her team write that the company has also seen the largest decrease in short interest in her coverage universe as of the end of November. The move comes as Valeant rose from less than $15 in mid-month to nearly $22 today.

  • Reuters4 days ago

    CANADA STOCKS-TSX advances, lifted by Valeant, financial services

    Canada's main stock index rose on Tuesday, led by gains in drugmaker Valeant Pharmaceuticals and in the financial services sector. * At 10:18AM ET , the Toronto Stock Exchange's S&P/TSX composite index ...

  • Tuesday’s Vital Data: Tesla Inc (TSLA), Apple Inc. (AAPL) and Valeant Pharmaceuticals International, Inc. (VRX)
    InvestorPlace4 days ago

    Tuesday’s Vital Data: Tesla Inc (TSLA), Apple Inc. (AAPL) and Valeant Pharmaceuticals International, Inc. (VRX)

    U.S. stock futures are trending cautiously higher this morning, as focus remains on the Federal Reserve and the central bank’s interest rate policy. Against this backdrop, Dow Jones Industrial Average futures are up 0.18%, S&P 500 futures have added 0.10% and Nasdaq-100 futures are higher by 0.02%. Taking a closer look at Monday’s options activity, Tesla Inc (NASDAQ:TSLA) calls and puts were active as reports emerged that “hundreds” of Model 3s are now showing up at delivery centers.

  • Benzinga4 days ago

    PreMarket Prep Trade Of The Day: Valeant Is On Fire

    Every day on PreMarket Prep, hosts Joel Elconin and Dennis Dick highlight over a dozen key morning movers to keep an eye on throughout the day. Below is a trade we thought is particularly hot today. Valeant ...

  • Investopedia4 days ago

    Valeant Stock Poised for Strong 2018 Gains

    Valeant stock is showing signs of heavy accumulation following a brutal drug pricing scandal and could reach the upper $30s in 2018.

  • Valeant Climbs to Its Highest Level in More Than a Year
    Bloomberg5 days ago

    Valeant Climbs to Its Highest Level in More Than a Year

    Don’t look now, but Valeant Pharmaceuticals International Inc. is at its highest level in more than a year.